Systemic fungal infections are a major problem in bone marrow transplant recipients who have prolonged neutropenia or who receive high-dose corticosteroids. Prophylaxis with Fluconazole or low-dose amphotericin B reduces, but does not eliminate these infections. To determine which prophylactic agent is better, we performed a prospective randomized study. 
Intense cytotoxic therapy combined with hematopoietic stem cell rescue is now front-line or salvage treatment for a variety of malignancies. However, this form of treatment is associated with an abundance of severe side-effects, either directly from the cytotoxic therapy or arising from the ensuing myelosuppression. 1, 2 Foremost among these toxicities is infection associated with neutropenia. [3] [4] [5] [6] These infectious consequences remain despite reduction in the duration of neutropenia with the use of hematopoietic growth factors such as G-CSF or GM-CSF.
Opportunistic fungal infections were uncommon prior to the initiation of dose-intensive therapy. 7 Two clinical situations predominate -fungemia and dissemination with yeast forms and pulmonary infection with hyphal organisms. 2, 8 The contribution of neutropenia to fungal infections is noted by approximately a 15% incidence after therapy of acute leukemia or marrow transplantation. [9] [10] [11] Fungal infections require long-term treatment and even with prompt initiation of therapy, lead to substantial mortality. 12 Overall, fungal infections account for more than 50% of infection-related mortality during neutropenia. 13 The standard of therapy for serious fungal infections is amphotericin B, although its administration can be limited by side-effects. 14 Lipid-associated or liposomal ampho-tericin B provides some protection against renal toxicity and infusion-related chills and fever. [15] [16] [17] [18] [19] The triazoles are a newer class of anti-fungal agents with a much improved toxicity profile compared with amphotericin B. 20 A number of prophylactic approaches have been implemented to protect neutropenic patients from fungal infections. [21] [22] [23] [24] [25] [26] [27] One study used low-dose amphotericin B (0.1 mg/kg/day) to prevent fungal infections after autologous marrow transplantation and showed a reduction in colonization but not invasive infection. 28 Aerosolized amphotericin B, suggested to be useful for prophylaxis, was not confirmed as effective in a randomized evaluation. 29, 30 A recent study using 2 mg/kg/day of liposomal amphotericin three times a week demonstrated little toxicity, but did not show a significant reduction in fungal infections. 31 Three large-scale series have compared Fluconazole and oral placebo, either in patients with acute leukemia or those undergoing bone marrow transplantation. [9] [10] [11] These trials demonstrated a substantial reduction in the incidence of colonization and/or invasive fungal infection and showed that Fluconazole is an appropriate agent for fungal prophylaxis in patients with prolonged neutropenia. However, it is still possible that aggressive empiric use of anti-fungals would be as successful as prophylaxis. Additionally, amphotericin B is an antifungal with a greater spectrum of activity including Aspergillus species and yeast forms, such as Candida kruseii, that are resistant to Fluconazole. 32 Here, we describe a trial conducted by The North American Marrow Transplant Group (NAMTG) comparing Fluconazole with amphotericin B for antifungal prophylaxis in patients undergoing dose-intensive therapy. Our study indicates that Fluconazole and amphotericin B have similar efficacy but Fluconazole is less toxic.
Methods
The study was a prospective, randomized, stratified and non-blinded trial comparing antifungal prophylaxis with amphotericin B with Fluconazole. Patients were stratified into three groups; matched related allogeneic marrow (allo) transplants, matched unrelated allogeneic (MUD) transplants and autologous marrow or stem cell (PBSC) transplants. These strata were chosen due to the anticipated difference in fungal infection rate with each type of transplant. Patients were randomized at each study center.
The primary endpoint of the study was the incidence of proven fungal infection. Secondary endpoints were suspected fungal infection, duration of fever, duration of hospitalization, duration of absolute neutropenia Ͻ500/l, fungal colonization of skin and gastrointestinal tract, use of intensified empiric amphotericin B therapy for suspected fungal infection, toxicities of anti-fungal prophylaxis, and patient survival to the time of hospital discharge. Followup of patients after hospital discharge was not undertaken. These endpoints were established prospectively. Patients eligible for entry into the trials were required to be у18 years old, give written informed consent approved by the treating institution's IRB, be undergoing dose-intensive therapy and hematopoietic stem cell (marrow or peripheral blood) transplantation with an anticipated duration of neutropenia of at least 10-14 days, have no clinical evidence of infection at the time of study entry, have no known allergy or intolerance to the study drugs, have no laboratory evidence of significant hepatic or renal dysfunction (defined as a SGOT or SGPT у4 × upper limit of normal, total bilirubin у3 × upper limit of normal and serum creatinine у2 × upper limit of normal) and not be actively receiving antibiotics or non-topical anti-fungal therapy with either Fluconazole or amphotericin B. All patients were required to receive prophylactic antibiotics active against gramnegative bacteria until resolution of neutropenia. The specific antibiotic for gram-negative prophylaxis, addition of additional antibiotics for fever and the use of prophylactic antibiotics to prevent gram-positive infection was defined by standard care at each treatment center.
Fluconazole was administered at a dose of 400 mg/day orally or intravenously for patients unable to tolerate oral administration. Amphotericin B was administered intravenously at a daily dose of 0.2 mg/kg (based on ideal body weight) with a maximum dose of 20 mg. Both drugs were begun at the conclusion of the cytotoxic therapy (1 day prior to stem cell infusion) and continued until recovery of neutrophils (Ͼ 500/l), unless a severe adverse reaction due to the prophylactic drug occurred.
Prophylaxis was stopped and high-dose amphotericin B (0.5-0.7 mg/kg/day) was initiated with documentation of any proven invasive fungal infection. A proven fungal infection required positive culture from a normally sterile source or histologic evidence of invasive fungal elements in tissue section. Empiric high-dose amphotericin B replaced prophylactic treatment for suspected fungal infection. Suspected fungal infection was defined as fever Ͼ38°C persisting for 3-5 days without positive blood cultures. There were thus three reasons for failure of prophylaxis: (1) adverse event, (2) proved fungal infection and (3) suspected fungal infection.
Toxicity was graded using the NAMTG marrow transplant toxicity system which is similar to the toxicity scale of Bearman et al. 33 This system grades toxicities from 0-4 using the following generalization: grade 0 = none; grade 1 = mild; grade 2 = severe; grade 3 = life-threatening; and grade 4 = fatal. In our study, the major toxicity noted was renal and the definitive scale for this organ system is: 
Statistical design and analysis
The trial was designed to detect a 10% difference in fungal infection incidence (primary endpoint) with an ␣ error of 0.05 and ␤ error of 0.10 (power of 90%) assuming the incidence of infection in the inferior group was 15%. A total of 187 patients were scheduled to enter each treatment arm. Proportions were compared by the method of Simon and required confirmation by chi-square analysis. Group comparison for continuous variables were compared with t-tests or Wilcoxon rank sum test.
Results

From 21 July 1992 to 16
October 1994 a total of 355 patients were entered into the trial. The distribution of patients at each treatment center and strata is shown in Table 1 . Imbalance at one treatment center (Baylor University Medical Center) was due to a misinterpretation of the autologous randomization codes. Patient diagnoses (data not shown) were of equal distribution (P Ͼ 0.05) between the two prophylactic groups. Additional demographic parameters are shown in Table 2 . None of these comparisons are statistically different except creatinine (P = 0.05) among related allogeneic recipients receiving amphotericin B (median 0.91 mg/dl, range 0.5-1.4) compared with Fluconazole-treated patients (median 0.77 mg/dl, range 0.5-1.2). However, all creatinine values (as required by the eligibility criteria) were normal (р1.4 mg/dl). Therefore, all treatment groups were comparable for pre-treatment features that could influence development of fungal infection or toxicity.
The most critical feature for the development of fungal infection is the duration of neutropenia. Table 3 indicates that the distribution of neutropenia was similar between treatments for all groups and strata. Overall, 47.4% (95% confidence interval 40.6-54.4%) and 57.9% (95% confidence interval 50.1-65.3%) of all patients receiving prophylaxis with Fluconazole and amphotericin B respectively, stopped prophylaxis early. These frequencies did not differ significantly either globally or by type of marrow transplant. Duration of prophylaxis is also shown in Table 3 and did not differ between amphotericin B or Fluconazole or by transplant strata. Table 4 reviews the reasons noted for discontinuation of prophylactic anti-fungal therapy. As shown, 43.9% (95% confidence interval 38.9-49.1%) of all patients had their prophylaxis discontinued because of persistent fever while Bone Marrow Transplantation Table 3 Overall results on broad-spectrum anti-bacterials. Documented fungal infection developed during prophylaxis in 2.3% (95% confidence interval 1.1-4.4%) including 2.6% and 1.9% (P Ͼ 0.05) of patients receiving Fluconazole or amphotericin B, respectively. Neither the rate of documented fungal infection nor of suspected fungal infection differed significantly between Fluconazole or amphotericin B groups globally or by strata as shown in Table 4 . However, drug toxicity leading to discontinuation of prophylaxis was statistically more frequent in amphotericin B recipients. Twenty such patients (12.6%, 95% confidence interval of 8.3-18.6%) developed toxicity with 13 having renal toxicity. Renal toxicity was categorized as grade 2 in nine patients and grade 3 in four. Three patients required dialysis while receiving amphotericin B. The baseline creatinine values of the 13 patients who developed renal toxicity were normal with a median of 0.75 mg/dl (range 0.5-1.1) and not different from the Fluconazole-treated patients (median 0.82 mg/dl, range 0.4-1.6). The other seven tox- icities were six episodes of infusion-related fever and chills and one episode of hepatic dysfunction. By contrast, only one Fluconazole recipient (0.5%, 95% confidence interval 0.1-2.8%) undergoing autologous transplantation developed drug toxicity (skin rash) requiring termination of prophylaxis. In analysis of the individual strata, 19%, 42.9% and 8.3% of patients undergoing allogeneic related, allogeneic unrelated and autologous transplants, respectively, developed toxicity while receiving prophylactic amphotericin B. The incidence of renal toxicity was 16.3% in all allogeneic recipients and 4.5% in autologous recipients (P Ͻ 0.05).
Parameter
Overall, 5.6% (95% confidence intervals of 3.7-8.5%) of the patients entered into the study ultimately developed a documented fungal infection including 4.1% and 7.5% (P Ͼ 0.05) of patients receiving Fluconazole or amphotericin B, respectively (Table 5 ). These included infections noted during and after discontinuation of prophylaxis. The frequency of infection did not differ between prophylactic groups or by type of marrow transplantation. Fungal infection in recipients of amphotericin B prophylaxis was caused by Candida albicans in eight patients, Candida glabrata in one patient, Candida parapsilosis in two patients and Aspergillus sp. in one patient. In recipients of Fluconazole prophylaxis, fungal infection was caused by Candida albicans in two patients, Candida glabrata in three patients, Candida parapsilosis in one patient, Candida krusei in two patients and Aspergillus sp. in two patients (two patients had dual infections with Candida glabrata combined with either Aspergillus sp. or Candida krusei. These infections were predominantly blood stream (15) with the remaining pulmonary (four) and genitourinary (one).
One hundred and ten patients receiving amphotericin B and 147 patients receiving Fluconazole underwent surveillance cultures of throat and rectum during prophylaxis. Forty-eight (43.6%, 95% confidence interval 34.7-53.0%) and 40 (27.2%, 95% confidence interval 20.7-34.9%) of the patients receiving amphotericin B and Fluconazole, respectively, developed a positive surveillance culture during prophylaxis (P Ͻ 0.01).
Death during therapy occurred in 19 patients (11.9%, 95% confidence interval 7.8-17.9%) receiving amphotericin B and in 24 patients (12.2%, 95% confidence interval 8.3-17.6%) receiving Fluconazole (P Ͼ 0.05). Causes of death included progressive neoplastic disease, toxicity, infection and graft-versus-host disease. Two patients in the amphotericin B arm (1.3%, 95% confidence interval 0.3-4.5%) and five patients in the Fluconazole arm (2.6%, 95% confidence interval 1.1-5.8%) died directly from a fungal infection (P Ͼ 0.05). Data on the duration of therapeutic amphotericin B, total dose of therapeutic amphotericin B, duration of fever and total duration of hospitalization are shown in Table 5 . Comparison of these values between recipients of amphotericin B or Fluconazole did not show any significant differences.
Discussion
The results of this trial are consistent with other reports showing successful prophylaxis of serious fungal infections after dose-intensive therapy for cancer. Utilizing either Fluconazole or amphotericin B, we observed an overall invasive fungal infection rate of 5.6%. Since we did not have an untreated or placebo control group, this number must be compared to historically-derived data. The incidence of fungal infection seen in this trial is quite similar to the rates (2.8-7.0%) seen in the Fluconazole treatment arms of three large randomized trials. [9] [10] [11] In their placebo control arms, these trials had a fungal infection rate of 8.0-18%.
The ultimate aim of our study was to compare the antifungal efficacy of Fluconazole and amphotericin B. The results showed therapeutic equivalence. However, amphotericin B was more toxic especially in allogeneic transplant patients due to a higher rate of renal dysfunction. Considering this toxicity, further evaluation of additional allogeneic transplant, to increase the statistical power for this group of patients, would not seem warranted. The increased toxicity was likely due to the nephrotoxic effect of combining amphotericin B with the immunosuppressive agents cyclosporine or tacrolimus. Patients who developed renal toxicity had normal serum creatinine values (median 0.75 mg/dl, range 0.5-1.1) prior to initiation of prophylaxis.
It still remains unclear whether prophylactic approaches lead directly to improved survival since careful clinical observation and rapid institution of empiric anti-fungal therapy will enable most patients to recover, especially with concurrent recovery of neutropenia. 10 The study by Goodman et al did not show improved overall survival although death due to invasive fungal infection was reduced by prophylaxis. On the other hand, the study by Slavin et al 11 Bone Marrow Transplantation in which Fluconazole was continued into the postengraftment period did show improved survival. Our study, without an untreated control arm, cannot resolve this issue. Negative aspects of prophylaxis, such as the substantial emergence of resistant organisms were not noted in our study.
The choice of amphotericin B dosing was an important aspect of this trial. 34 Since our study did not demonstrate the superiority of amphotericin B, it is possible that we used a 'sub-optimal' dose. Supporting this hypothesis is the lack of success of a lipid formulation for prophylaxis when used at doses less than recommended for therapeutic administration. 31 It is also possible that we could have achieved similar efficacy and avoided toxicity with a lower amphotericin B dose.
The prophylactic use of lipid formulations of amphotericin B might overcome the dose-limiting toxicity of conventional amphotericin B. However, these formulations were not readily available during the design of our trial. In addition, a comparative trial would have to be massive to detect an improvement in the 4.1% rate of fungal infections seen with Fluconazole prophylaxis.
Fungal infections developed in a total of 5.6% of our patients. Most of these infections were due to yeast forms and 19 of the 22 isolates were due to Candida species (10 albicans, two krusei, three parapsilosis and four glabrata). The remainder were due to Aspergillus sp. infections. Thus, most of these infections were likely to be sensitive to Fluconazole and Candida krusei was only isolated in two patients on the Fluconazole arm. Candida krusei is an uncommon isolate even at centers using Fluconazole routinely, and one major outbreak was likely due to nosocomial spread from a point source. 32 Seventy percent of the patients in our trial underwent surveillance cultures, an adequate number for valid observation. Fluconazole was superior in the prevention of colonization with yeasts as detected by oral and rectal surveillance cultures. Since this was not associated with a significant reduction in the actual number of invasive infections, its clinical significance is uncertain. Our results are similar to previous reports using Fluconazole. 35 This trial was not designed to evaluate the prevention of fungal infections in long-term follow-up. Aspergillosis remains the most problematic fungal infection after engraftment, at least in allogeneic transplant recipients. We had hoped that prophylactic amphotericin B would offer some protection against Aspergillus as suggested in another study. 36 However, during the study only three infections with Aspergillus were noted, divided between prophylactic arms. This may have been due to the aggressive use of empiric high-dose (0.5-0.7 mg/kg/day) of amphotericin B for persistently febrile patients.
The requirement for the initiation of therapeutic dose amphotericin B was planned using a conventional definition of presumed fungal infection, ie 3-5 days of unexplained fever occurring while patients were receiving broad-spectrum anti-bacterial antibiotics. This practice was developed prior to the widespread use of anti-fungal prophylaxis. In our study, only 3.4% of patients were proven to have a fungal infection after discontinuation of prophylaxis. Thus, it is possible that in patients receiving prophylaxis, the introduction of therapeutic doses of amphotericin B could be delayed for longer durations of fever (eg Ͼ7-10 days) or for more definitive criteria (eg pulmonary infiltrates without known bacterial cause). 37 In summary, we have demonstrated that low-dose amphotericin B (0.2 mg/kg/day) and Fluconazole (400 mg/day) are equivalent for prophylaxis of fungal infection after dose-intensive cytotoxic therapy followed by stem cell transplantation. However, especially in allogeneic transplant recipients, the greater safety of Fluconazole makes it the preferred agent.
